Battling defiant leukemia cells

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine.

Chronic myeloid leukemia (CML) is an aggressive cancer of the blood that is often treated with a drug called Imatinib (a.k.a. Gleevec). Although Gleevec is highly effective, some cancer can develop resistance to the drug. The mechanism that drives this resistance is not completely understood, but there is evidence that cancerous stem-like cells are particularly resistant and help to perpetuate disease.

CML stem-like cells rely on a called ?-catenin for their survival and maintenance, and deletion of this protein in mice delays cancer growth. Another protein, IRF8, inhibits the survival of cells and is often reduced in CML cells, particularly in patients with advanced disease.

A group of scientists from the Max Delbrück Center for Molecular Medicine in Berlin now show that CML cells with activating ?-catenin mutations are particularly resistant to Imatinib. Resistance is boosted further when this defect teams up with those that abolish IRF8 expression, rendering CML cells highly aggressive in mice. In fact, in CML cells lacking IRF8, ?-catenin activation was essential for the cell's growth and survival.

Combined treatment with drugs that restore the expression of IRF8 and those that inactivate ?-catenin may force these cells to surrender to treatment, preventing fatal leukemia progression.


Explore further

To prevent leukemia's dreaded return, go for the stem cells

More information: Scheller, M., et al. 2013. J. Exp. Med. DOI: 10.1084/jem.20130706
Journal information: Journal of Experimental Medicine

Citation: Battling defiant leukemia cells (2013, October 7) retrieved 23 October 2019 from https://medicalxpress.com/news/2013-10-defiant-leukemia-cells.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more